For research use only. Not for use in humans.

Anti-human MHC Class I (HLA-A, HLA-B, HLA-C)-InVivo

Synonyms: HLA class I, HLA-A/B/C Clone No.:W6/32

Anti-human MHC Class I (HLA-A, HLA-B, HLA-C)-InVivo reacts with the human major histocompatibility complex (MHC) class I, HLA-A, B, and C. All human nucleated cell express MHC class I antigens associated with β2-microglobulin. MHC class I plays a central role in cell-mediated immune responses and tumor surveillance.

Anti-human MHC Class I (HLA-A, HLA-B, HLA-C)-InVivo

Click to purchase the isotype control of Anti-human MHC Class I (HLA-A, HLA-B, HLA-C)-InVivo

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A217202 Purity: 99% Protein concentration: 7.00 mg/ml Endotoxin Level: <1EU/mg
99

Product Details

Molecular Weight 150 kDa
Clone W6/32
Isotype mouse IgG2a,κ
Application Anti-human MHC Class I (HLA-A, HLA-B, HLA-C)-InVivo
Source CHO
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS, pH 7.0. Contains no stabilizers or preservatives
Murine Pathogen Screening Panel all targets tested yielded Negative Results: Theiler’s Murine Encephalomyelitis Virus, Ectromelia (Mousepox) Virus, Hantavirus, Polyomavirus, Sendai Virus, Mycoplasma pulmonis, Pneumonia Virus of Mice, K Virus, Mouse Parvovirus, Mouse Hepatitis Virus, Mouse Norovirus, Mouse Minute Virus, Mouse Cytomegalovirus, Mouse Adenovirus, Lactate Dehydrogenase-Elevating Virus, Reovirus Panel, Lymphocytic Choriomeningitis Virus, Mouse Rotavirus.
Storage
(From the date of receipt)
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06246149 RECRUITING Drug: Tebentafusp Uveal Melanoma European Organisation for Research and Treatment of Cancer - EORTC 2024-11-11 PHASE3
NCT06942442 RECRUITING Drug: Physician's Choice|Drug: Tebentafusp HLA-A*0201 Positive Cells Present; Clear Cell Sarcoma (CCS) Sarcoma Alliance for Research through Collaboration 2025-10-22 PHASE2
NCT07645469 RECRUITING Drug: Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 T Acute Myeloid Leukemia Fred Hutchinson Cancer Center 2026-09-01 PHASE1
NCT07145450 RECRUITING PDAC Anocca AB 2025-07-03 PHASE1; PHASE2
NCT07583316 NOT_YET_RECRUITING Drug: CRPA1A2 Lung Cancer (Locally Advanced or Metastatic); Esophagus Cancer; Head and Neck Cancer; Hepatocellular Carcinoma (HCC) Corregene Biotechnology Co., Ltd 2026-05-29 PHASE1
NCT05751798 RECRUITING Drug: Part A: OSE-279 100mg|Drug: Part A: OSE-279 300mg|Drug Solid Advanced Tumor; Lymphoma; NSCLC (Non-small Cell Lung Cancer) OSE Immunotherapeutics 2022-12-20 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-06-30)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.